Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

Sponsor
AbbVie
Study ID
NCT03518047
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • risankizumab — DRUG
    rizankizumab subcutaneous (SC) infusion
  • placebo for rizankizumab — DRUG
    placebo for rizankizumab subcutaneous (SC) infusion

Study Details

The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.

Key Dates

Start date
Jul 19, 2018
Status verified
Jan 2021
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020

Study Design

Enrollment
50 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Placebo for risankizumab by subcutaneous (SC) injection.
  • Experimental: Risankizumab
    Risankizumab by subcutaneous (SC) injection.

Primary Outcome Measure

Proportion of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16 [ Time Frame: Week 16 ]

Related Studies